Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Quality of life · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Adverse events · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found